Skip to main content
Fig. 1 | Journal of Ovarian Research

Fig. 1

From: The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

Fig. 1

The sensitivity analyses. Abbreviation: PFS, progression-free survival; PD, progressive disease; HRD, homologous recombination deficiency; BRCA, breast cancer susceptibility genes; WTP, willingness-to-pay; QALY, quality-adjusted life-year. Note-Orange background indicates that ICER for olaparib plus bevacizumab versus bevacizumab are lower than WTP, while blue represents that ICER are higher than WTP

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us